Efficacy And Safety Of Liposome-Paclitaxel/Liposome-Paclitaxel Combined With S-1 In Advanced Gastric Cancer Patients With Poor Performance Status

Objective:To observe the efficacy and safety of liposome-paclitaxel/liposome-paclitaxel plus S-1 in advanced gastric cancer patients with poor performance status and provide experience of using liposome-paclitaxel to treat similar patients.Methods:We have observed 20 advanced gastric cancer patients with poor performance status.The chemotherapy regimen was liposome-paclitaxel single-agent and liposome-paclitaxel combined with S-1.Initially,if the patient could not tolerate the 2-drug combination chemotherapy regimen,only liposome-paclitaxel single-agent was given.When the patient’s physical condition improves,plus S-1.All patients were evaluated for tumor response according to the Response Evaluation Criteria in Solid Tumors guidelines(version 1.1).Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria(version 4.0).Median overall survival(OS)and progression-free survival(PFS)were calculated using the Kaplan-Meier method.Results:Of the 20 patients,complete response(CR)accounted for 10.00%(2/20),partial response accounted for 30.00%(6/20),stable disease accounted for 25.00%(5/20),and progressive disease accounted for 35.00%(7/20).The objective response rate and disease control rates were 40.00%(8/20),and 65.00%(13/20),respectively.The median progression-free survival(PFS)and median overall survival(OS)were 6.5months(95%confidence interval:4.41-8.59)and 28.0 months(95%confidence interval:6.85-49.15),respectively.The most common hematological toxicities were neutropenia and anemia.Conclusions:Liposome-paclitaxel/liposome-paclitaxel plus S-1 in the treatment of advanced gastric cancer patients with poor performance status can prolonged the patients’PFS and OS and the toxicity are tolerable.